Id1-Induced IGF-II and Its Autocrine/endocrine promotion of esophageal cancer progression and chemoresistance-implications for IGF-II and IGF-IR-targeted therapy

Clinical Cancer Research

Volumn 20, Issue 10, 2014, Pages 2651-2662

  Li, Bin ^a,b   Tsao, Sai Wah ^a,b   Chan, Kwok Wah ^a,b   Ludwig, Dale L ^d   Novosyadlyy, Ruslan ^d   Li, Yuk Yin ^a   He, Qing Yu ^c   Cheung, Annie L M ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Center for Cancer Research   (Hong Kong)

^c JINAN UNIVERSITY   (China)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CIXUTUMUMAB; FLUOROURACIL; INSULIN LIKE GROWTH FACTOR TYPE 1 RECEPTOR; PROTEIN KINASE B; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; UNCLASSIFIED DRUG; ANTI-IGF-1R ANTIBODY A12; ANTINEOPLASTIC ANTIMETABOLITE; ID1 PROTEIN, HUMAN; INHIBITOR OF DIFFERENTIATION 1; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER TISSUE; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DNA BINDING; DRUG EFFICACY; ENDOCRINE FUNCTION; ENZYME ACTIVATION; ESOPHAGEAL CANCER CELL LINE; ESOPHAGUS CANCER; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN TARGETING; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENDOCRINE SYSTEM; ESOPHAGEAL NEOPLASMS; GENETICS; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; SECONDARY; TUMOR CELL LINE; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIMETABOLITES, ANTINEOPLASTIC; AUTOCRINE COMMUNICATION; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENDOCRINE SYSTEM; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; INSULIN-LIKE GROWTH FACTOR II; LUNG NEOPLASMS; MICE; MICE, NUDE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901036167     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2735     Document Type: Article

References (36)

1. Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet 2009;25:30-8.
2. Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray MA, et al. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest 2011;121:784-99.
3. Rick FG, Schally AV, Szalontay L, Block NL, Szepeshazi K, Nadji M, et al. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc Natl Acad Sci U S A 2012;109:1655-60.
4. Xie Q, Bradley R, Kang L, Koeman J, Ascierto ML, Worschech A, et al. Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A 2012;109:570-5.
5. Mo W, Chen J, Patel A, Zhang L, Chau V, Li Y, et al. CXCR4/CXCL12 mediate autocrine cell-cycle progression in NF1-Associated malignant peripheral nerve sheath tumors. Cell 2013;152:1077-90.
6. Chatterjee S, Heukamp LC, Siobal M, Schottle J, Wieczorek C, Peifer M, et al. Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest 2013;123:1732-40.
7. Li B, Cheung PY, Wang X, Tsao SW, Ling MT, Wong YC, et al. Id-1 activation of PI3K/Akt/NFkappaB signaling pathway and its significance in promoting survival of esophageal cancer cells. Carcinogenesis 2007;28:2313-20.
8. Perk J, Iavarone A, Benezra R. Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer 2005;5:603-14.
9. Wong YC, Wang X, Ling MT. Id-1 expression and cell survival. Apoptosis 2004;9:279-89.
10. Yuen HF, Chan YP, Chan KK, Chu YY, Wong ML, Law SY, et al. Id-1 and Id-2 are markers for metastasis and prognosis in oesophageal squamous cell carcinoma. Br J Cancer 2007;97:1409-15.
11. Zha J, Lackner MR. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 2010;16:2512-7.
12. Heidegger I, Pircher A, Klocker H, Massoner P. Targeting the insulinlike growth factor network in cancer therapy. Cancer Biol Ther 2011;11:701-7.
13. Imsumran A, Adachi Y, Yamamoto H, Li R, Wang Y, Min Y, et al. Insulinlike growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis 2007;28:947-56.
14. Chava S, Mohan V, Shetty PJ, Manolla ML, Vaidya S, Khan IA, et al. Immunohistochemical evaluation of p53, FHIT, and IGF-II gene expression in esophageal cancer. Dis Esophagus 2012;25:81-7.
15. Hu YC, Lam KY, Law SY, Wan TS, Ma ES, Kwong YL, et al. Establishment, characterization, karyotyping, and comparative genomic hybridization analysis of HKESC-2 and HKESC-3: two newly established human esophageal squamous cell carcinoma cell lines. Cancer Genet Cytogenet 2002;135:120-7.
16. Shimada Y, Imamura M, Wagata T, Yamaguchi N, Tobe T. Characterization of 21 newly established esophageal cancer cell lines. Cancer 1992;69:277-84.
17. Kawamata H, Furihata T, Omotehara F, Sakai T,Horiuchi H, Shinagawa Y, et al. Identification of genes differentially expressed in a newly isolated human metastasizing esophageal cancer cell line, T.Tn-AT1, by cDNA microarray. Cancer Sci 2003;94:699-706.
18. Hui CM, Cheung PY, Ling MT, Tsao SW, Wang X, Wong YC, et al. Id-1 promotes proliferation of p53-deficient esophageal cancer cells. Int J Cancer 2006;119:508-14.
19. Li B, Tsao SW, Li YY, Wang X, Ling MT, Wong YC, et al. Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway. Int J Cancer 2009;125:2576-85.
20. Li B, Li YY, Tsao SW, Cheung AL. Targeting NF-kappaB signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancer. Mol Cancer Ther 2009;8:2635-44.
21. McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008;133:994-1005.
22. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007;13: 5549s-55s.
23. Ling MT, Lau TC, Zhou C, Chua CW, Kwok WK, Wang Q, et al. Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF). Carcinogenesis 2005;26:1668-76.
24. Dong Z, Wei F, Zhou C, Sumida T, Hamakawa H, Hu Y, et al. Silencing Id-1 inhibits lymphangiogenesis through down-regulation of VEGF-C in oral squamous cell carcinoma. Oral Oncol 2011;47:27-32.
25. Cullen KJ, Smith HS, Hill S, Rosen N, Lippman ME. Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res 1991;51:4978-85.
26. Kim HT, Choi BH, Niikawa N, Lee TS, Chang SI. Frequent loss of imprinting of the H19 and IGF-II genes in ovarian tumors. Am J Med Genet 1998;80:391-5.
27. Nonomura N, Miki T, Nishimura K, Kanno N, Kojima Y, Okuyama A. Altered imprinting of the H19 and insulin-like growth factor II genes in testicular tumors. J Urol 1997;157:1977-9.
28. Schirmacher P, Held WA, Yang D, Chisari FV, Rustum Y, Rogler CE. Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res 1992;52:2549-56.
29. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, et al. Gene expression profiles in normal and cancer cells. Science 1997;276:1268-72.
30. Fong S, Itahana Y, Sumida T, Singh J, Coppe JP, Liu Y, et al. Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc Natl Acad Sci U S A 2003;100:13543-8.
31. Minn AJ, GuptaGP, SiegelPM, BosPD, Shu W,GiriDD, et al.Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
32. Scagliotti GV, Novello S. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev 2012;38:292-302.
33. Rustum YM. Thymidylate synthase: a critical target in cancer therapy? Front Biosci 2004;9:2467-73.
34. You F, Aoki K, Ito Y, Nakashima S. AKT plays a pivotal role in the acquisition of resistance to 5-fluorouracil in human squamous carcinoma cells. Mol Med Rep 2009;2:609-13.
35. Yoshida T, Miyoshi T, Seike J, Yamai H, Takechi H, Yuasa Y, et al. Gene expression changes in a chemoresistant model with human esophageal cancer xenografts using cDNA microarray. Anticancer Res 2009;29:1163-8.
36. Vinod BS, Antony J, Nair HH, Puliyappadamba VT, Saikia M, Narayanan SS, et al. Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil. Cell Death Dis 2013;4:e505.